Pharmacokinetics of Ifosfamide Administered According to Three Different Schedules in Metastatic Soft Tissue and Bone Sarcomas

REFERENCES

• Antman KH. Chemotherapy of advanced sarcomas of bone and soft tissue. Semin Oncol 1992; 6, Suppl 12: 13–22.
   Google Scholar
• Gad El Mowha. Ifosfamide in advanced pancreatic cancer: a five year experience. Cancer Chemother Pharmacol 1986; 18, Suppl 2: S55–S56.
   PubMedGoogle Scholar
• Ardizzoni A, Fusco V Gulisano M, Pronzato P, Baracco F. Etoposide, ifosfamide and cisplatin in the treatment of advanced non small cell lung cancer. Cancer Treat Rep 1987; 71: 1311–1312.
   PubMedGoogle Scholar
• Cabanillas F. Ifosfamide combinations in lymphoma. Semin Oncol 1990; 2, Suppl 4: 58–62.
   Google Scholar
• Lare PC, Garcia-Puche JL, Pedraza V. Cisplatin-ifos-famide in neoadjuvant chemotherapy in stage IIIB cervical uterine squamous cell carcinoma. Cancer Chemother Pharmacol 1990; 26 (S): 36-38.
   Google Scholar
• Lund B, Hansen M, Handen OP, Hansen HH. Combined high dose carboplatin and cisplatin and ifosfamide in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1990; 8: 1226–1230.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Cooper K, Geller NL, Bajorin DF, Dmitrovsky E. The role of ifosfamide plus cisplatin based chemotherapy as salvage therapy for patients with refractory germ cell tumours. Cancer 1990; 66: 2476–2481.
   PubMed Web of Science ®Google Scholar
• Wolf M, Havemann K, HoIle R, Gropp C, Drings P. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small cell lung cancer: a multicenter German randomized trial. J Clin Oncol 1987; 5: 1880–1889.
   PubMed Web of Science ®Google Scholar
• Millward MS, Harris AL, Contwell BMJ. Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. Cancer 1990; 65: 2421–2425.
   PubMed Web of Science ®Google Scholar
• Sarosy G. Ifosfamide - pharmacologic overview. Semin Oncol 1989; 1, Suppl 3: 2–8.
   Google Scholar
• Soddy AV, Cole M, Pearson DDJ, Idle JR. The kinetic of the autoinduction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacolt1995; 36: 53–60.
   PubMed Web of Science ®Google Scholar
• Shaw IC, Graham MI. Mesna: a short review. Cancer Treat Rev 1987; 14: 67–86.
   PubMed Web of Science ®Google Scholar
• Casali P, Pastorino U, Azzarelli A, et al. Prospectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. Cancer Chemother Pharmacol 1993; 31, Suppl. 2: 228-232.
   Google Scholar
• Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard and highdose schedules. Semin Oncol 1990; 2, Suppl 4: 68–73.
   Google Scholar
• Toma S, Palumbo R, Comandone A, et al. Ambulatory 4-days continuous infusion schedule of high dose ifosfamide with mesna uroprotection and granulocyte colony stimulating factor in advanced solid tumours: a phase I study. Ann Oncol 1995; 6: 193–196.
   PubMed Web of Science ®Google Scholar
• Bertulli M, Casali P, Mastore M, Santoro A, Bonadonna G. High dose ifosfamide as a second line chemotherapy for advanced adult soft tissue sarcomas patients. Ann Oncol 1994; 5, Suppl 8: 878.
   Google Scholar
• Brain E, La Cosne A, Le Chevalier T. High dose Ifosfamide can circumvent resistance to standard dose if os-famide in advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 1993; 12, 470: 1641.
   Google Scholar
• Patel S, Benjamin RS. Standard and high dose chemo-therapy for advanced soft tissue sarcomas. Ann Oncol 1992; 3, Suppl. 2: 81-83.
   Google Scholar
• Buonadonna A, Romanini A, Comandone A, Della Palma M, Verusio C, Frustaci S. Increasing continuous infusion ifosfamide and bolus epirubicin in soft tissue sarcoma patients. Proc Am Soc Clin Oncol 1996; 522: 1683.
   Google Scholar
• Brade WP, Herdrick K, Varini M. Ifosfamide pharmacology, safety and therapeutical potential. Cancer Treat Rev 1985; 12: 1–47.
   PubMed Web of Science ®Google Scholar
• Haney D, Lewis JJ, Bailey CC. Acute ifosfamide induced tubular toxicities. Correspondence, Lancet 1989; 2: 103–104.
   Web of Science ®Google Scholar
• Brock N. Oxazaphosphorine cytostatics: past-present-future. Cancer Res 1989; 49: 1–7.
   PubMed Web of Science ®Google Scholar
• Smeitink J, Verreussel M, Schroder C, Lippens R. Nephrotoxicity associated with ifosfamide. Eur J Ped 1988; 148: 164–166.
   PubMed Web of Science ®Google Scholar
• van Dyk JJ, Falksan HC, van der Merwe AM, Falkson G. Unexpected toxicity in patients treated with ifosfamide. Cancer Res 1972; 32: 921–924.
   PubMed Web of Science ®Google Scholar
• Kurowski V, Wagner T. Comparative phamacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993; 33: 36–42.
   PubMed Web of Science ®Google Scholar
• Lewis LD, Fitzgerald DL, Harper PG, Rogers HS. Fractionated ifosfamide therapy produces a time dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990; 30: 725–732.
   PubMed Web of Science ®Google Scholar
• Brade WP, Herdrich K, Araujo CE. Dosing and side-effects of ifosfamide plus mesna. J Cancer Res Clin Oncol 1991; 117, Suppl. 4: 164-186.
   Google Scholar
• Soddy AV, Jule SM, Wyllie L, Price R, Pearson ADI, Idle JR. Pharmacokinetics and metabolism in children of ifos-famide administered as a continuous infusion. Cancer Res 1993; 53: 3758–3764.
   PubMed Web of Science ®Google Scholar
• Soddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR. Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 1995; 31A, 5: 785–790
   PubMed Web of Science ®Google Scholar
• Rustum AM, Hofmma NE. Determination of cyclophos-famide in whole blood and plasma by reversed-phase high performance liquid chromatography. J Chromatogr 1987; 422: 125–134.
   PubMed Web of Science ®Google Scholar
• Leone L, Comandone A, Oliva C, et al. Stability of ifos-famide in solution for multiday infusion by external pump. Anticancer Drugs 1995; 6: 604–607.
   PubMed Web of Science ®Google Scholar
• Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988; 37: 301–355.
   PubMed Web of Science ®Google Scholar
• Wagner T, Ehninger G. Self induction of cyclophos-phamide and ifosfamide metabolism by repeated high dose treatment. In Brade et al (eds), Ifosfamide in tumours therapy. Contribution to Oncology Karger, Basel, 1987: vol. 26, 69–75.
   Google Scholar